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Innervation of the bone marrow (BM) has been described more than one century
ago, however the first in vivo evidence that sympathoadrenergic fibers have a role in
hematopoiesis dates back to less than 25 years ago. Evidence has since increased
showing that adrenergic nerves in the BM release noradrenaline and possibly also
dopamine, which act on adrenoceptors and dopaminergic receptors (DR) expressed
on hematopoietic cells and affect cell survival, proliferation, migration and engraftment
ability. Remarkably, dysregulation of adrenergic fibers to the BM is associated with
hematopoietic disturbances and myeloproliferative disease. Several adrenergic and
dopaminergic agents are already in clinical use for non-hematological indications and
with a usually favorable risk-benefit profile, and are therefore potential candidates for
non-conventional modulation of hematopoiesis.
Keywords: dopamine, noradrenaline, adrenaline, adrenoceptors, dopaminergic receptors, hematopoiesis,
neuroimmune phamacology, drug repurposing
Introduction
The term ‘‘niche’’, derived from the Latin word ‘‘mytilus’’ (mussel), has eventually come to
designate a shallow recess in a wall, as for a statue or other decorative object, in view of the
similarity with the shape of a seashell, and broadly a place suitable or appropriate for a person or
thing. In biology and medicine, the use of ‘‘niche’’ to designate the microenvironment where cells
are found, and which may determine their fate, becomes increasingly popular in the early 90’s of
the last century, thereafter steadily rising, from 27 papers/year on average in the period 1991–2000
(including about 3, 4 dealing with stem cells) to more than 1000/year since 2011 (about two thirds
of them dealing with stem cells; Figure 1). So far, niches for several types of stem cells have been
identified and characterized, including neurogenic (Bjornsson et al., 2015), osteogenic (Bianco,
2011), epithelial (Secker and Daniels, 2009), hematopoietic (Mendelson and Frenette, 2014).
The hematopoietic stem cell (HSC) niche as an organized microenvironment that controls
HSC homeostasis was first proposed in Schofield (1978) and thereafter much progress has
been made in characterizing the different cell types that are essential in HSC maintenance and
regeneration (Lymperi et al., 2010; Wang and Wagers, 2011; Mendelson and Frenette, 2014),
including perivascular stromal cells, reticular cells, endothelial cells, macrophages as well as
sympathoadrenergic nerve terminals.
Sympathetic fibers innervating the bone marrow (BM) were described at least 70 years
ago (Kuntz and Richins, 1945), their stimulation resulting in the release of reticulocytes and
neutrophils into systemic circulation (DePace and Webber, 1975), however for many years their
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role was mainly related to the regulation of the permeability
of the venous sinusoids and the mobility of BM cells, until the
evidence was provided that chemical sympathectomy increases
the number of peripheral blood leukocytes after syngeneic BM
transplantation in mice, an effect which is mimicked by the
α1-adrenoceptor antagonist prazosin (Maestroni et al., 1992).
Nowadays, sympathetic nerves are considered, together with the
hypothalamus-pituitary-adrenal axis, the main communication
pathway between the brain and the immune system (Elenkov
et al., 2000; Marino and Cosentino, 2013) and about one
hundred papers have been published dealing with adrenergic
modulation of hematopoiesis (Figure 1). It appears therefore
that, despite sympathetic innervation of the BM has been known
for decades, sympathoadrenergic modulation of hematopoiesis
involves so far relatively few scientists around the world,
a somewhat paradoxical observation in view of the many
significant therapeutic opportunities which could arise from this
field of research.
We will hereafter review current knowledge on innervation
of the BM and on sympathoadrenergic modulation of
hematopoiesis, discussing available evidence in light of the
opportunity to repurpose adrenergic (and possibly also
dopaminergic) agents as modulators of hematopoiesis.
Indeed, any dirrectly and indirectly acting adrenergic and
dopaminergic therapeutics are currently used for non-
hematological indications, and could thus represent an attractive
source of non-conventional agents for the modulation of the
hematopoietic process. To this end, a brief general introduction
to the neuroimmune pharmacology of catecholamine
neurotransmitters will be first provided.
FIGURE 1 | Temporal trends of papers indexed in PubMed. (Alexandru
Dan Corlan. Medline trend: automated yearly statistics of PubMed results for
any query, 2004. Web resource at URL: http://dan.corlan.net/medline-trend.
html. Accessed: 2015-03-24. Archived by WebCite at http://www.webcitation.
org/65RkD48SV).
Neuroimmune Pharmacology of
Catecholamine Neurotransmitters
Noradrenaline is a neurotransmitters in the central and
peripheral nervous systems, and to a lesser extent a
neurohormone in chromaffin cells in medulla of adrenal
glands. From the locus coeruleus (LC), axons project rostrally,
dorsally, and caudally to spinal cord, affecting attention, arousal
and vigilance, and regulating hunger and feeding behavior.
Adrenaline is a minor neurotransmitter in the central nervous
system (CNS), however it is the main neurohormone secreted
by the adrenal medulla. In periphery, noradrenaline is the main
transmitter of sympathetic postganglionic fibers. Peripheral
adrenergic actions include: smooth muscles contraction (skin,
kidney, and mucous membranes blood vessels), stimulation
of sweat glands, relaxation gut wall, bronchi, skeletal muscle
blood vessels, increases of heart rate and contraction force. In
addition, they have prominent metabolic (increased liver and
muscle glycogenolysis, increased lipolysis) and endocrine actions
(e.g., modulation of insulin and renin secretion). Dopamine
is a key neurotransmitter in the brain, where it is involved
in a wide variety of CNS functions including motivation,
cognition, movement and reward. Besides being biochemically
and metabolically related (since are all produced from the non-
essential amino acid tyrosine; Figure 2), several lines of evidence
suggest that dopamine may be stored in and released from
sympathetic nerve terminals, thus acting as a transmitter even at
this level (Bell, 1988; Bencsics et al., 1997). Detailed discussion
of dopamine, noradrenaline and adrenaline neurochemistry,
anatomy and physiology can be found in Feldman et al. (1997).
FIGURE 2 | Biosynthesis of dopamine, noradrenaline and adrenaline.
Synthesizing enzymes and enzyme cofactors are shown close to each arrow.
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Pharmacology of Dopamine, Noradrenaline and
Adrenaline
Dopamine, noradrenaline and adrenaline act on
7-transmembrane, G-protein coupled receptors. Dopaminergic
receptors (DR) exist in five different molecular subtypes,
grouped into two families according to their pharmacology and
second messenger coupling: the D1-like (D1 and D5) activating
adenylate cyclase and the D2-like (D2, D3 and D4) inhibiting
adenylate cyclase (Beaulieu and Gainetdinov, 2011; Alexander
et al., 2013; Cosentino et al., 2013). Adrenoceptors (ARs) are
nine different receptors, including three major types—α1, α2 and
β—each further divided into three subtypes (Alexander et al.,
2013). DR agonists are used to treat Parkinson’s disease (PD),
restless leg syndrome, and hyperprolactinemia, while antagonists
are used as antipsychotics and antiemetics (Table 1). AR
agonists and antagonists are used to treat hypertension, angina
pectoris, congestive heart failure, asthma, depression, benign
prostatic hypertrophy, and glaucoma, as well as other conditions
such as shock, premature labor and opioid withdrawal, and
as adjunct medications in general anaesthesia (Table 2).
Pharmacological modulation of adrenergic and dopaminergic
pathways can be obtained also by use of indirectly acting
agents. All the steps involved in dopamine, noradrenaline
and adrenaline synthesis, storage and release, uptake and
metabolism represent the target of several drugs already in use
for non-immune indications (e.g., cardiovascular, neurologic,
neuropsychiatric). Pharmacological targets and examples of
therapeutic drugs are listed in Tables 3 and 4 (Cosentino et al.,
2013).
Adrenergic Pathways in the Modulation of the
Immune Response
The two major pathway are involved in the brainimmune
cross-talk are the hypothalamic-pituitary-adrenal axis and the
sympathetic nervous system. The role of the sympathetic nervous
system in the neuroimmune crosstalk has been the subject of
several reviews (Elenkov et al., 2000; Nance and Sanders, 2007;
Flierl et al., 2008; Cosentino and Marino, 2013; Marino and
Cosentino, 2013). The predominant view includes the release
of noradrenaline by sympathoadrenergic terminals, followed
by activation of β2-ARs finally resulting into antiinflammatory
effects (including to a variable extent the inhibition of T helper
(Th) 1 proinflammatory cytokines such as IFN-γ, IL-12, TNF-α,
and the enhancement of Th2 cytokines such as IL-10 and
and transforming growth factor, TGF-β). Notably however
noradrenaline may also promote IL-12-mediated differentiation
of naive CD4+ T cells into Th1 effector cells which eventually
produce IFN-γ (Swanson et al., 2001; Cosentino et al., 2013).
Although β-ARs are considered the main interface between
sympathoadrenergic terminals and immune cells, α-ARs may
also occur in immune cells where they elicit proinflammatory
responses, as in the case of α1-ARs on human macrophages
(Grisanti et al., 2011) and of α2-ARs on rodent phagocytes (Flierl
et al., 2007).
Dopaminergic Pathways in the Modulation of the
Immune Response
In comparison to noradrenaline and adrenaline, the immune
effects of dopamine emerged only recently but very quickly
attracted increasing attention (reviewed in Basu and Dasgupta,
2000; Sarkar et al., 2010; Levite, 2012). DR are expressed in
most if not all human immune cells, including T and B cells,
dendritic cells, macrophages, microglia, neutrophils and NK
cells, and immune cells can ‘‘meet’’ dopamine not only in
brain but also in blood, lymphoid organs and in several other
peripheral tissues, such as the kidney and the hepatic vasculature
(reviewed by Levite, 2012; Cosentino et al., 2013). Among human
immune cells, CD4+CD25high T lymphocytes are specifically
sensitive to the activation of D1-like receptors expressed on their
membrane, resulting in inhibition of the regulatory functions of
this specialized cell subset, which usually suppresses the activity
of effector T cells (Cosentino et al., 2007). Dopamine is also
an emerging regulator of dendritic cell and T cell physiology,
with critical implications for onset of immune-related disorders
(Pacheco et al., 2009).
Immune Cells as a Source of Dopamine,
Noradrenaline and Adrenaline
Several types of immune cells may produce store and
utilize catecholamines as autocrine/paracrine transmitters. The
synthesis of dopamine, noradrenaline and adrenaline in immune
cells likely occurs by means of a classical pathway, as suggested
FIGURE 3 | Expression of vesicular monoamine transporters
(VMAT2) and Dopamine β-hydroxylase (DBH) in human
peripheral blood mononuclear cells (PBMCs). TOTO-3 iodide
(642/660) was used for staining of nuclei. Cells were prepared at the
Center for Research in Medical Pharmacology, University of Insubria,
Varese (I) and analysis was performed at the Consorzio
MIA—Microscopy and Image Analysis, Faculty of Medicine, University
of Milan Bicocca, Milan (I).
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TABLE 1 | Examples of dopaminergic agonists and antagonists currently used as therapeutic drugs (brand names in parentheses).
Agonists
D1-like Fenoldopam mesylate (Corlopam)
D1-like/D2-like Ergot Alkaloids: bromocriptine (Parlodel); pergolide (Permax); cabergoline (Dostinex)
Non-Ergot Alkaloids: apomorphine (Apokyn); rotigotine (Neupro)
D2-like Non-Ergot Alkaloids: pramipexole (Mirapex); ropinirole (Requip)
Antagonists
Typical antipsychotics
chlorpromazine (Thorazine), fluphenazine (Prolixin), haloperidol (Haldol), loxapine (Loxitane), molindone (Moban), perphenazine (Trilafon), pimozide
(Orap), thioridazine (Mellaril), thiothixene (Navane), trifluoperazine (Stelazine)
A typical antipsychotics
amisulpride (Solian), clozapine (Clozaril), olanzapine (Zyprexa), quetiapine (Seroquel), risperidone (Risperdal), sulpiride (Dogmatil), ziprasidone
(Geodon)
Antiemetics
domperidone, metoclopramide (Reglan), prochlorperazine (Compazine)
by the presence of the enzyme tyrosine hydroxylase (TH, EC
1.14.16.2), the first and rate-limiting enzyme in the synthesis
of catecholamines, which undergoes upregulation following
cell stimulation. TH inhibition, e.g., by α-methyl-p-tyrosine,
prevents intracellular enhancement of catecholamines (Musso
et al., 1996; Bergquist and Silberring, 1998; Cosentino et al.,
1999, 2002a,b; Marino et al., 1999; Reguzzoni et al., 2002). In
human peripheral blood mononuclear cells (PBMCs) stimulated
in vitro with with phytohemagglutinin (PHA), TH mRNA
expression and catecholamine production occur only in T and
B lymphocytes (but not in monocytes) and are reduced by
dopaminergic D1-like receptor activation (Ferrari et al., 2004),
as well as by the proinflammatory cytokine IFN-γ, which
in turn is counteracted by IFN-β (Cosentino et al., 2005).
Human lymphocytes possess reserpine-sensitive compartments
and vesicular monoamine transporters (VMAT) which are
involved in intracellular storage of catecholamines (Marino et al.,
1999; Cosentino et al., 2000, 2007; Figure 3). Catecholamine
release can be induced by biological agents such as IFN-β
(Cosentino et al., 2005) or by elevation of extracellular K+
([K+]e; Cosentino et al., 2003). Human lymphocytes also express
membrane transporter for dopamine (DAT; Marino et al., 1999;
Marazziti et al., 2010) and for noradrenaline (NET; Audus and
Gordon, 1982).
Innervation of the BM and of other
Hematopoietic Organs and Tissues
Primary lymphoid organs, such as BM and thymus, as well as
secondary lymphoid organs, such as spleen and lymph nodes,
are innervated by autonomic sympathoadrenergic efferent nerve
fibers. The sympathetic nervous system and the hypothalamic-
pituitary-adrenal axis are the major pathway connecting the
CNS and the immune system (reviewed in Elenkov et al., 2000).
Several excellent reviews discuss in detail the origin, distribution,
signaling and targets of sympathetic nerves in lymphoid organs
(Felten et al., 1985; Felten and Felten, 1988; Felten, 1991; Straub,
2004), the effect of age (Bellinger et al., 1992; Madden et al.,
1995, 1997, 1998; Friedman and Irwin, 1997) and stress (Irwin,
1994; Marshall and Agarwal, 2000; Nagatomi et al., 2000; Sloan
et al., 2008) as well as the relevance of dysregulated sympathetic
nerovus system in immune-mediated disease (Bellinger et al.,
1992, 2008; Madden et al., 1995; Friedman and Irwin, 1997;
Marshall and Agarwal, 2000; Frohman et al., 2001; Straub et al.,
2006; Wrona, 2006; del Rey and Besedovsky, 2008; Benarroch,
2009).
Sympathoadrenergic Modulation
of Hematopoiesis
Until the early 80 s, interest on adrenergic regulation of BM
function was essentially concentrated on erythropoiesis (see e.g.,
Beckman et al., 1980; Lipski, 1980; Mladenovic and Adamson,
1984), with a few work dedicated to thrombocytopoiesis
(Ganchev and Negrev, 1989).
Maestroni et al. (1992) were the first describing adrenergic
modulation of hematopoiesis in an in vivo model, showing that
chemical sympathectomy by 6-hydroxydopamine (6-OHDA)
significantly increased the number of peripheral blood leukocytes
after syngeneic BM transplantation in mice, an effect which
was mimicked by the α1-AR antagonist prazosin. Results were
reproduced in normal mice (Maestroni and Conti, 1994), by
showing that prazosin can also enhance myelopoiesis and
platelet formation, while noradrenaline and the α1-adrenergic
agonist methoxamine could directly inhibit the in vitro growth
of granulocyte/macrophage-colony-forming unit (GM-CFU).
The order of potency of α-adrenergic antagonists on the
effect of noradrenaline was prazosin>phentolamine>yohimbine.
On these basis, the authors suggested that prazosin binds
specifically to both BM cell membranes and intact BM cells, on
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TABLE 2 | Examples of dopaminergic agonists and antagonists currently used as therapeutic drugs.
α1AR
Agonists Methoxamine, methylnorepinephrine, midodrine, oxymetazoline, metaraminol, phenylephrine
Indications Vasoconstriction and mydriasis, used as vasopressors, nasal decongestants and eye exams
Antagonists Alfuzosin, doxazosin, phenoxybenzamine, phentolamine, prazosin, tamsulosin, terazosin, trazodone
Indications Hypertension, benign prostatic hyperplasia
α2-AR
Agonists Dexmedetomidine, medetomidine, romifidine, clonidine, brimonidine, detomidine, lofexidine, xylazine, tizanidine, guanfacine, amitraz
Indications Antihypertensives, sedatives and treatment of opiate dependence and alcohol withdrawal symptoms
Antagonists Phentolamine, yohimbine, idazoxan, atipamezole, trazodone, mianserin, mirtazapine
Indications Aphrodisiac, antidepressants, reversal of α2-AR agonist-induced sedation
β-AR
β1-AR
Agonists Dobutamine, isoprenaline, noradrenaline
Indications Bradycardia, heart failure, cardiogenic shock
Antagonists Metoprolol, atenolol, bisoprolol, propranolol, timolol, nebivolol
Indications Cardiac arrhythmia, congestive heart failure, glaucoma, myocardial infarction, migraine prophylaxis
β2-AR
Agonists Short-acting: salbutamol, levosalbutamol, terbutaline, pirbuterol, procaterol, clenbuterol, metaproterenol, fenoterol, bitolterol mesylate, ritodrine,
isoprenaline. Long-acting: salmeterol, formoterol, bambuterol, clenbuterolUltra-long-acting: indacaterol
Indications Asthma (effects: dilation of bronchial passages, vasodilation in muscle and liver, relaxation of uterine muscle, and release of insulin)
Antagonists Butoxamine, timolol, propranolol
Indications Glaucoma, heart attacks, hypertension, migraine headache; investigational: stage fright, PTSD
β3-AR
Agonists Amibegron (investigational: antidepressant, anxiolytic), solabegron (overactive bladder, irritable bowel syndrome)
Antagonists SR 59230A
two distinct binding sites, one with a Kd of 0.98 ± 0.32 nM and
a Bmax of 5 ± 2.9 fM/2 × 106 cells (higher affinity site), and
another with a Kd of 55.9 ± 8.2 nM and a Bmax of 44 ± 7.7
fM/mg protein. Several lines of evidence suggest that the higher
affinity site is actually an α1-AR, while the low affinity binding
site remains to be characterized. The high-affinity binding is
due to a lymphoid/stem cell fraction with no blasts and no
GM-CFU progenitors, while the low-affinity site was apparent
on a fraction enriched with GM-CFU progenitor cells (Maestroni
and Conti, 1994). An initial summary of the significant evidence
so far provided was published in Maestroni (1995), emphasizing
the ability of α-AR antagonists to enhance myelopoiesis and
platelets production while decreasing lymphopoiesis, in both
normalmice as well as after BM transplantation. AR agonists, like
the sympathetic neurotransmitter noradrenaline, seem to inhibit
myelopoiesis, and effect which might be of clinical relevance,
since it rescues the blood forming system and improves the
survival of mice injected with a lethal dose of carboplatin or
exposed to X-ray irradiation. This effect is apparently mediated
by activation of α1-ARs expressed in pre-B cells, in turn inducing
the production of TGF-β, which is finally responsible for the
haematopoietic effects (Maestroni, 1995). Remarkably, it has
been recently shown that nonmyelinating Schwann cells, which
ensheath autonomic nerves in the BM, maintain HSC dormancy
by activating latent TGF-β and that glial cell death and loss
of HSC result from autonomic denervation of BM (Yamazaki
et al., 2011). Noradrenaline was most effective at 3 mg/kg, s.c.,
and protected 77% of the mice injected i.v. with 200 mg/kg
of carboplatin, which has a LD100 of 170 mg/kg. The effects
was profoundly antagonized by the α1-AR antagonist prazosin.
In vitro, 1 µM noradrenaline rescued GM-CFU in unseparated
BM cells containing the adherent population expressing the
high affinity α1-AR, another effect which was consistently
counteracted by low concentrations of the α1-AR antagonist
prazosin (0.1 nM-10 nM; Togni and Maestroni, 1996). Such
results apparently challenge early reports suggesting that in
vitro the β-AR agonist isoproterenol might result in increased
proliferation and sensitivity of HSC to cytotoxic agents, an
effect which was inhibited by the β-AR antagonist propranolol
(Byron, 1972), however the studies cannot be directly compared
due to fundamental differences in the experimental models and
in the pharmacological agents employed. Interestingly, it was
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TABLE 3 | Pharmacological targets for the modulation of dopaminergic and adrenergic pathways by agents targeting storage and release (brand/street
names in parentheses).
Reuptake inhibitors/transporter blockers
DAT inhibitors Methylphenidate (Ritalin, Focalin, Concerta), bupropion (Wellbutrin, Zyban), amineptine (Survector, Maneon,
Directin), nomifensine (Merital, Alival), cocaine, methylenedioxypyrovalerone (MDPV; “Sonic”), ketamine (K; Ketalar,
Ketanest, Ketaset; “Special-K”, “Kit Kat”, etc.), phencyclidine (PCP; Sernyl; “Angel Dust”, “Rocket Fuel”, etc.)
Indications Attention-deficit hyperactivity disorder (ADHD), narcolepsy, obesity as anorectics, depression and anxiety, drug
addiction, sexual dysfunction, illicit street drugs
VMAT2 inhibitors Reserpine (Serpasil), tetrabenazine (Nitoman, Xenazine), deserpidine (Harmonyl)
Indications Sympatholytics or antihypertensives, antipsychotics
Releasing agents Amphetamine (Adderall, Dexedrine; “Speed”), lisdexamfetamine (Vyvanse), methamphetamine (Desoxyn;
“Meth”, “Crank”, “Crystal”, etc.), methylenedioxymethamphetamine (MDMA; “Ecstasy”, “E”, “X”, “XTC”, etc.),
phenmetrazine (Preludin; “Prellies”), pemoline (Cylert), 4-methylaminorex (4-MAR; “Ice”, “Euphoria”, etc.),
benzylpiperazine (BZP; “Bennies”, “A2”, “Sunrise”, “Frenzy”, etc.)
Indications Attention-deficit hyperactivity disorder (ADHD), narcolepsy, obesity, depression and anxiety, drug addiction, sexual
dysfunction, illicit street drugs
“Activity enhancers” Benzofuranylpropylaminopentane (BPAP), phenylpropylaminopentane (PPAP)
Indications Investigational: Alzheimer’s disease, Parkinson’s disease and clinical depression
DAT, dopamine transporter; VMAT2, vesicular monoamine transporter type 2.
recently shown that also dopamine (50 mg/kg/days × 7 days
i.p.), besides inhibiting tumor angiogenesis and growth of HT29
human colon cancer and Lewis lung carcinoma (LLC) in mice,
also did not cause hypertension, hematological, renal and hepatic
toxicities in normal, HT29 and LLC tumor bearing animals,
and also prevented 5-fluorouracil (5FU) induced neutropenia in
HT29 colon cancer bearing mice, an action apparently mediated
through inhibition of 5FU mediated suppression of GM-CFU in
the BM (Sarkar et al., 2014). In subsequent studies (Maestroni
et al., 1997), it was further confirmed that noradrenaline
administration in mice rescued hematopoiesis from the toxic
effect of the chemotherapeutic agent carboplatin administered
at supralethal doses (200 mg/kg), possibly by protecting GM-
CFU. Meanwhile, Afan et al. (1997) reported that denervation
decreases femoral cellularity as well as progenitor cells while
mobilizing these cells in the peripheral blood of splenectomized
mice. In non splenectomized animals, these changes were quickly
cleared (Afan et al., 1997).
The consistent effects of noradrenaline and dopamine
in the BM raised immediately the question regarding their
physiological relevance and in particular the origin of
catecholamines at this level. By use of a high performance
liquid chromatographic method, we therefore measured
endogenous catecholamines in BM from normal, 6-OHDA-
treated and pargyline-treated mice. Noradrenaline levels were
lower after 6-OHDA and higher after pargyline, while adrenaline
and dopamine were not affected in either conditions (Marino
et al., 1997). In the BM however noradrenaline, as well as the
other catecholamines dopamine and adrenaline, may originate
not only from nerve fibers but also from hematopoietic and
immune cells themselves (Maestroni et al., 1998). In particular,
in murine BM we described a daily rythmicity for noradrenaline
and dopamine, with peak values occurring at night. Chemical
sympathectomy disrupted the rhythm, whereas adrenaline
showed no rhythmicity or 6-OHDA sensitivity. Noradrenaline
was also positively associated with the proportion of cells
in the G2/M and S phases of the cell cycle. Remarkably,
in Méndez-Ferrer et al. (2008) published an elegant article
suggesting just the opposite, i.e., that noradrenaline release
in mouse BM is higher during the day/light hours. However,
the findings of Maestroni et al. (1998) cannot be compared
directly with those of Méndez-Ferrer et al. (2008) because the
latter did not measure catecholamine concentration in the BM
as Maestroni et al. did. The circadian release of noradrenaline
was inferred by indirect experiments such as denervation, use
of gene knock-out mice, and the catecholamine function was
mimicked by injection of adrenergic agonists and/or antagonists.
In addition, Maestroni et al. (1998) showed that BM cells
themselves do contain catecholamines, therefore catecholamines
in the BM resulted from both neural and hematopoietic cell
contribution. Hence, Méndez-Ferrer et al. (2008) detected only
one component of the system that was related to HSC trafficking
while Maestroni et al. (1998) found a correlation between
noradrenaline and BM cell proliferation. However, both groups
found that chemical sympathectomy by 6-OHDA abolished
the rhythm. Thus, a possible hypothetical interpretation that
might reconcile these divergent findings is that the light/dark
rhythm synchronizes the suprachiasmatic nucleus in the CNS
which, in turn, entrains the sympathoadrenergic rhythm
in the BM regulating the HSC traffic. In addition, the very
same sympathetic nervous system or other circadian signals
might affect clock genes in hematopoietic cell progenitors,
influencing their noradrenaline content and their proliferation.
Consistently, it has been reported that noradrenaline may
affect clock genes expression (Morioka et al., 2010). Another
circadian signal that ensues at the beginning of the activity
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TABLE 4 | Pharmacological targets for the modulation of dopaminergic and adrenergic pathways by agents targeting metabolism (brand/street names in
parentheses).
Reuptake inhibitors/transporter blockers
Monoamine oxidase inhibitors Nonselective agents: phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan)MAOA
selective agents: moclobemide (Aurorix, Manerix) MAOB selective agents: selegiline (Eldepryl,
Zelapar, Emsam), rasagiline (Azilect), pargyline (Eutonyl) Harmala alkaloids: harmine, harmaline,
tetrahydroharmine, harmalol, harman, norharman
found to varying degrees in Nicotiana tabacum (Tobacco; also cigarettes, cigars, chew, hookah, etc.),
Banisteriopsis caapi (Ayahausca, Caapi, Yage), Peganum harmala (Harmal, Syrian Rue), Passiflora
incarnata (Passion Flower), and Tribulus terrestris (Puncture Vine), among others
Indications Depression and anxiety, Parkinson’s disease (PD) and dementia, for the recreational purpose
Catechol O-methyl transferase (COMT) inhibitors Entacapone (Comtan, Stalevo), tolcapone (Tasmar), nitecapone
Indications Parkinson’s disease (PD)
DOPA decarboxylase (DDC) inhibitors Benserazide (Prolopa, Madopar, etc.), carbidopa (Lodosyn, Atamet, Parcopa, Sinemet, Stalevo, etc.),
methyldopa (Aldomet, Aldoril, Dopamet, Dopegyt, etc.)
Indications Parkinson’s disease (PD), sympatholytic or antihypertensive agents
Dopamine β-hydroxylase (DBH) inhibitors Disulfiram (Antabuse)
Indications Drug addiction as an anticraving agent
Dopamine β-hydroxylase (DBH) inhibitors Disulfiram (Antabuse)
Indications Drug addiction as an anticraving agent
Tyrosine hydroxylase (TH) inhibitors Metirosine (Demser)
Indications Pheochromocytoma (PCC) as sympatholytic/antihypertensive agent
Others Hyperforin and adhyperforin [Hypericum perforatum (St. John’s Wort (SJW))], L-theanine [Camellia
sinensis (Tea Plant, also known as Black, White, Oolong, Pu-erh, or Green Tea)], and S-adenosyl-L-
methionine (SAMe)
Indications Dietary supplements for depression and anxiety
period coinciding in rodents with the night is the adrenal
corticosteroid output that is well known to affect clock genes
expression. Interestingly, corticosteroids may also increase
noradrenaline uptake in neuroblastoma cells (Sun et al.,
2010) and this might happen also in BM cells containing
catecholamines.
Circadian variation of the activity of sympathoadrenergic
fibers innervating the bone may also affect bone homeostasis.
Early studies indeed described increased bone remodeling during
light periods in rodents (Simmons and Nichols, 1966). It is
now established that β2-ARs are expressed in osteoblasts and
osteoclasts and their stimulation triggers an osteoclastogenic
response, while β1-AR actvation may result in bone protection,
and even β3-ARs may indirectly affect skeleton homeostasis
through their effects in other tissues (e.g., the adipose tissue).
According to the current hypothesis, increased sympathetic
activity could be associated with osteoporosis and the use of
β-blockers might result in increased bone mineral density and
decreased risk of fractures, although the clinical relevance of such
effects is still under scrutiny (reviewed in Elefteriou et al., 2014).
Daily rythmicity of BM catecholamines likely contributes
to the circadian control of the immune system, which is
now emerging as important regulator of specific immune
functions (Scheiermann et al., 2013). In addition, Maestroni
et al. (1998) found noradrenaline and dopamine in both short-
term and long-term BM cultures as well as in human or
murine B lymphoid cell lines, an observation which subsequently
prompted thorough investigation of endogenous production of
catecholamines by immune cells (Marino et al., 1999). The
ability of immune cells to produce and utilize catecholamines
likely underlies novel opportunities for the targeted modulation
of the immune response: as an example, we described in
human CD4+CD25+ regulatory T lymphocytes the occurrence
of an autocrine/paracrine loop involving dopaminergic pathways
and resulting in down-regulation of their regulatory function
(Cosentino et al., 2007), which is apparently involved in
autoimmune disease such as multiple sclerosis (Cosentino et al.,
2012).
In recent times, interest has risen for dopamine regulating
bone marow hematopoiesis. By mans of flow cytometry Spiegel
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et al. (2007) showed that human CD34+ cells expressed both
DR D3 and DR D5 on their surfaces. The more primitive
CD34+CD38lo cell populations had higher expression of
both DR D3 and DR D5 than did the more differentiated
CD34+CD38hi cells. Interestingly, dopaminergic agonists
increased the polarization and motility of CD34+ cells, as well as
their clonogenic progenitor content and engraftment potential.
In the same study, by means of flow cytometry, it was shown
that human CD34+ cells expressed also the β2-AR, and G-CSF-
mobilized CD34+ cells had higher expression of the β2-AR than
did cord blood CD34+ cells. Adrenaline and noradrenaline
regulated CD34+ cell motility and proliferation, in vitro as well
as in vivo, possibily through a canonical Wnt signaling pathway
(Spiegel et al., 2007).
Effect of Stress on the Production
of Inflammatory Cells
Recently, increasing attention has been dedicated to the
mechanisms regulating the trafficking of HSC in the
bloodstream. Giudice et al. (2010) reviewed the mechanisms
regulating HSC trafficking, showing that circulating HSC
exhibit marked circadian fluctuations due to standard cycles
of 12 h light/12 h darkness and that circadian HSC oscillations
are strongly altered when mice are subjected to continuous
light for 2 weeks or to a jet lag. HSC fluctuation is likely in
antiphase with the expression of the chemokine CXCL12 in
the BM microenvironment. Both circadian HSC trafficking
and expression of CXCL12 are modulated by rhythmic release
of sympathoadrenergic transmitters in the BM (Giudice
et al., 2010). Several lines of evidence indeed suggest that
hematopoiesis may be subject to catecholaminergic regulation
even under extreme conditions, such as restraint stress and
cytostatic treatment (Dygai and Skurikhin, 2011), although also
the stress hormone corticosterone may exert major effects on
HSC in the BM, as suggested by increased HSC apoptosis and
reduced BM repopulation and stromal progenitor cell number
following high corticosterone exposure and, on the other side,
increased BM HSC and CXCL12 levels in animals with low
corticosterone levels or treated with the corticosterone synthesis
inhibitor metyrapone (Kollet et al., 2013). Indeed, transcriptome
representation analyses showed relative expansion of the selective
up-regulation of a subpopulation of immature proinflammatory
monocytes (Ly-6c(high) in mice, CD16(-) in humans) within the
circulating leukocyte pool in peripheral blood mononuclear cells
from people subject to chronic social stress (low socioeconomic
status) and mice subject to repeated social defeat (Powell et al.,
2013). The effect was ascribed to increased myelopoietic output
of Ly-6c(high) monocytes and Ly-6c(intermediate) granulocytes
in mice subject to repeated social defeat, and was blocked by
treatment with β-AR antagonists as well as with the myelopoietic
growth factor GM-CSF. On these basis the authors suggest that
sympathoadrenergic-induced up-regulation of myelopoiesis
results in a proinflammatory response possibly contributing to
the increased risk of inflammation-related disease associated
with adverse social conditions (Powell et al., 2013). The ability
of chronic stress to induce monocytosis and neutrophilia in
humans has been recently reproduced comparing medical ICU
residents either off duty or on ICU duty (Heidt et al., 2014), and
by use of rodent models it was shown that under conditions of
chronic variable stress in mice, sympathetic nerve fibers increase
the release of noradrenaline, which in turn signals BM niche
cells to decrease CXCL12 levels through β3-ARs. This leads to
increased HSC proliferation and subsequently increased output
of neutrophils and inflammatory monocytes (Heidt et al., 2014).
Interestingly, treatment of mice with noradrenaline, mimicking
acute stress, has been reported to increase circulating levels of
CXCL12, resulting in rapid mobilization of HSC, an effect which
is induced also by plerixafor (AMD3100), an immunostimulant
used to mobilize HSC, and blocked by injection of a β2-
AR antagonist (Dar et al., 2011), suggesting that acute and
chronic stress may result in different effects on the BM. The
pathological implications of chronic stress-induced monocytosis
and neutrophilia were tested in atherosclerosis-prone Apoe(–/–)
mice which, when subjected to chronic stress, accelerated
hematopoiesis and promoted plaque features associated with
vulnerable lesions that cause myocardial infarction and stroke in
humans (Heidt et al., 2014). Interestingly, a similar mechanism is
likely involved in the expanded neutrophil and monocyte supply
which may occur after stroke (Courties et al., 2015). Indeed, in
mice with transient middle cerebral artery occlusion (tMCAO),
flow cytometry and cell cycle analysis showed activation of
the entire hematopoietic tree, including myeloid progenitors
resulting in increased expression of myeloid transcription
factors, including PU.1, and declined lymphocyte precursors.
Notably, In mice after tMCAO, the levels of TH (the first and
rate-limiting enzyme in the synthesis of catecholamines) rose in
sympathetic fibers and BM noradrenaline levels increased, ass
hematopoietic niche factors that promote stem cell quiescence
decreased. In mice with genetic deficiency of the β3-AR, on the
contrary, HSCs did not enter the cell cycle in increased numbers
after tMCAO (Courties et al., 2015).
Repurposing of Adrenergic and
Dopaminergic Agents as Modulators
of Hematopoiesis in Health and Disease
The possibility to manipulate hematopoiesis by means
of sympathoadrenergic mechanisms provides enormous
therapeutic opportunities, also in view of the great amount
of adrenergic and dopaminergic agoniststs and antagonistts
and indirectly acting agens which are altready in clinical
use with a usually favorable therapeutic index (Marino and
Cosentino, 2013). Recently, Lucas et al. (2013) provided further
cofirmation that that sympathoadrenergic innervation of the BM
is crucial for hematopoietic regeneration after chemotherapy.
Maestroni et al. (1992) however, who first described in vivo
the adrenergic modulation of hematopoiesis, showed that
chemical sympathectomy by 6-hydroxydopamine (6-OHDA)
increased peripheral blood leukocytes after syngeneic BM
transplantation in mice. Lucas et al. (2013), on the contrary,
reported reduced survival in 6-OHDA-treated animals, and
differences are hardly explained by experimental conditions, as
both mice strain and gender, as well as chemical denervation
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protocol, are the same (except for additional 250 mg/kg of
6-OHDA on day 2 after the initial 100 mg/kg on day 0). In
addition, in the study by Maestroni et al. (1992) differences
between saline- ad 6-OHDA-treated animals were evident only
in animals kept under continuous 24-h lighting, and not in
those kept under a 12:12 light:dark cycle. Finally, in the study by
Maestroni et al. (1992) the effect of sympathetic denervation was
concentration-dependently mimicked by the α1-AR antagonist
prazosin, while the non selective β-AR antagonist propranolol
was without effect per se and selectively reverted the effect of
prazosin on platelets. Lucas et al. (2013) used only β2- and
β3-AR antagonists, and only at one dose, which resulted in
mild effects qualitatively similar to those of 6-OHDA. It is
possible that differences in the effects of 6-OHDA on BM
and circulating cell recovery may depend upon the different
doses used. In the article by Lucas et al. (2013) we found no
information concerning the actual effects of 6-OHDA on TH+
nerve endings in BM or on blood cells. Indeed, 6-OHDA can
exert direct toxicity on circulating lymphocytes (Del Rio and
Velez-Pardo, 2002), and high doses might be therefore less
selective for nerve endings. Anyway, clarifying such minor
methodological and procedural issues will pave the way for
clinical trial of adrenergic agents as promoters of hematopoietic
recovery.
Evidence obtained in rodents indicate that β2-AR agonists
may enhance mobilization of HSC and hematopoietic progenitor
cells. Katayama et al. (2006) showed that after administration
of the β2-AR agonist clenbuterol, the mobilization defect was
partly rescued inDbh−/−mice (lacking dopamine β-hydroxylase,
the enzyme which converts dopamine into noradrenaline)
and resulted in enhanced mobilization in Dbh+/− animals.
Clenbuterol was effective only before and during G-CSF
administration. The authors propose that the effect of G-CSF is
due to release of noradrenaline from sympathetic nerve endings
resulting in osteoblast suppression and reduced synthesis of
CXCL12, through the activation of β2-ARs which cooperate
with other signals from the G-CSF receptor (Katayama et al.,
2006).
Sympathoadrenergic agents may also contribute to restore
normal hematopoiesisis in myeloproliferative neoplasms.
Sympathoadrenergic fibers, supporting Schwann cells and
nestin(+) mesenchymal stem cells are reduced in the BM
of patients with myeloproliferative neoplasms as well as in
mice expressing the human JAK2(V617F) mutation in HSCs.
Interestingly, reduction of mesenchymal stem cells is due
to BM neural damage and Schwann cell death triggered
by IL-1β, resulting in expanded mutant HSC number
and accelerated myeloproliferative neoplasms progression.
Treatment with β3-AR agonists restore the sympathetic
regulation of nestin(+) mesenchymal stem cells, blocking
myeloproliferative neoplasms progression by indirectly
reducing the number of leukaemic stem cells (Arranz et al.,
2014).
Neuropathy of sympathoadrenergic fibers has been recently
proposed also as a novel mechanism for malignancies like
acute myelogenous leukemia (AML) to exploit the hematopoietic
microenvironment for its purposes (Hanoun et al., 2014). Indeed,
in an animal model of AML, of sympathetic nervous system
neuropathy promotes leukemic BM infiltration, possibly through
an expansion of perivascular mesenchymal stem and progenitor
cells primed for osteoblastic differentiation at the expense of
the physiological periarteriolar niche cells. Blockade of β2-AR
pathways enhanced AML infiltration whereas a β2-AR agonist
reduced disease activity.
As a final remark, we would like to mention the recently
emerging evidence which indicate the multiple ways in which
the local microenvironment may contribute to cancer-induced
bone disease, possibly through a key role of the sympathetic
nervous system providing bone homeostatic signals. Stress and
anxiety are able to cause bone loss through the sympathetic
nervous system, and have been shown to have an effect on
not only the osteolytic effect of breast cancer, but also the
metastatic infiltration of bone. Sympathetic nervous system
signaling to β-ARs on osteoblasts has also been implicated
in potentiating other signals, such as parathyroid hormone,
osteopontin and IGF-1, and release of HSCs from their
niche, which may also have implications for invading cancers.
Preliminary evidence have been recently summarized into an
excellent review (Olechnowicz and Edwards, 2014) and the
topic will likely attract the broadest interest in the near
future.
Conclusion
Although the first in vivo evidence for the role of
sympathoadrenergic fibers in the modulation of hematopoiesis
was provided less than 25 years ago (Maestroni et al., 1992), the
relevance of catecholaminergic modulation of hematopoiesis
rapidly raised thanks to several seminal studies showing the key
role of sympathoadrenergic fibers in the hematopoietic niche, as
well as the potential of adreneceptor ligands, and in some cases
even of dopamine receptor ligands (Sarkar et al., 2014).
In addition, the recently established notion that activation
of sympathoadrenergic represents a link between chronic stress
(e.g., due to adverse social conditions) and up-regulation
of proinflammatory responses, such as monocytosis and
neutrophilia in humans (see e.g., Heidt et al., 2014), not
only provides a mechanistic explanation to the negative
prognostic role of the neutrophil/lymphocyte ratio in a broad
and heterogeneous number of critical conditions, such as
cancer (Templeton et al., 2014) and cardiovascular disease
(Guasti et al., 2011; Bhat et al., 2013) but also offers several
opportunities for therapeutic intervention. Results obtained so
far in preclinical models would already support to various
extent the clinical evaluation of: the α1-AR antagonist prazosin
(Maestroni et al., 1992; Maestroni and Conti, 1994), β2-
AR agonists (Katayama et al., 2006; Dar et al., 2011)
and dopaminergic agonists (Spiegel et al., 2007) for HSC
transplantation; α1-AR agonists (Togni and Maestroni, 1996;
Maestroni et al., 1997) as well as dopaminergic agonists (Sarkar
et al., 2014) to protect against the adverse effects of cytotoxic
agents on BM; β-AR antagonists to reduce the proinflammatory
response associated with chronic stress (Powell et al., 2013;
Heidt et al., 2014); β2-AR agonists (Hanoun et al., 2014)
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and β3-AR agonists (Arranz et al., 2014) in myeloproliferative
disease.
Sympathoadrenergic innervation has finally reached
an established role in the complex network of neural and
neuroendocrine agents which regulate the hematopoietic system
(Maestroni, 2000). Several key questions still await answers,
including whether the neural regulation of hematopoiesis
plays any role in aplastic anemia, leukemia, and immune-
based diseases or during emergencies such as acute infections
and/or stress events: any positive response will provide the
conceptual framework for the straightforward development of
new pharmacological strategies, considering the availability
of several dopaminergic and adrenergic agents, already
in clinical use for non-immune indications and with a
usually favorable risk-benefit profile. Finally, from a general
point of view, these findings include hematology among
the fields which cannot but benefit from an integrative
neuroimmune pharmacological approach (Izeku and
Gendelman, 2008).
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